Home›Stock Screener›GlaxoSmithKline Pharmaceuticals

GlaxoSmithKline Pharmaceuticals Share Price Today | Stock Price & GlaxoSmithKline Pharmaceuticals Share Screener

GLAXO Pharmaceuticals & Biotechnology
Live Share Price NSE
₹2638.20
▼ -49.40 (-1.84%)
2026-11-18 00:00:00
Live Share Price BSE
₹2638.00
▼ -55.55 (-2.06%)
2026-11-18 00:00:00

As of November 18, 2026, the live GlaxoSmithKline Pharmaceuticals share price (NSE: GLAXO) is ₹2,638.20 on NSE and ₹2,638.00 on BSE, down 1.84% from the previous close, with shares trading between ₹2,620.20 and ₹2,699.00 in today's trading session, and a 52-week range of ₹2,103.20–₹3,106.40. Track GLAXO market cap trends to gauge the company's total market size. Use the GlaxoSmithKline Pharmaceuticals stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today GlaxoSmithKline Pharmaceuticals opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.

Key Statistics and Valuation Ratios

Over the trailing twelve months the company reported revenue of ₹1,256 and net income of ₹336, with EBITDA of ₹475, an operating margin of 34.0% and a profit margin of 26.8%.

GlaxoSmithKline Pharmaceuticals Market Cap ₹45,275.46 Cr.
GLAXO P/E Ratio (TTM) 39.20
GlaxoSmithKline Pharmaceuticals P/B Ratio 23.91
EPS (TTM) ₹61.15
Dividend Yield 2.15%
Debt to Equity 0.01
GLAXO 52 Week High ₹3106.40
GlaxoSmithKline Pharmaceuticals 52 Week Low ₹2103.20
Operating Margin 34.00%
Profit Margin 26.75%
GLAXO Revenue (TTM) ₹1,256.00
EBITDA ₹475.00
Net Income ₹336.00
Total Assets ₹4,324.00
Total Equity ₹2,267.00

GlaxoSmithKline Pharmaceuticals Share Price Chart

Track the current stock price of GlaxoSmithKline Pharmaceuticals with an interactive chart. Analyse GLAXO share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete GlaxoSmithKline Pharmaceuticals stock quote in one place.

The quote of ₹2,638.20 sits between the 52-week low of ₹2,103.20 and the 52-week high of ₹3,106.40, and the latest session moved -1.84% from the previous close.

GlaxoSmithKline Pharmaceuticals Company Profile - Fundamental Screener

Screen GlaxoSmithKline Pharmaceuticals company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for GLAXO shares across the equity market and its stock price history, plus the wider market trend.

The company is classified under the Healthcare sector and the Pharmaceuticals & Biotechnology industry, with Renu S. Karnad listed as chairperson or CEO, and it trades under ISIN INE159A01016.

Business Overview

GlaxoSmithKline Pharmaceuticals Limited is an Indian subsidiary of UK-based GSK Plc, engaged in manufacturing, distributing, and trading pharmaceuticals. The company operates in three main product areas: vaccines, specialty medicines, and general medicines. It has manufacturing facilities in Nashik and Thane, with a clinical development center in Bangalore. The company's portfolio...more

Company Details

Classification

Sector Healthcare
Industry Pharmaceuticals & Biotechnology
Sub-Sector Pharmaceuticals & Biotechnology
Segment E

Identifiers and Leadership

Chairperson/CEO Renu S. Karnad
ISIN INE159A01016

GlaxoSmithKline Pharmaceuticals Balance Sheet Screener

Screen GLAXO balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.

For 2026, total assets were ₹4,324, up from ₹4,108 in 2025.

Latest statistics put total assets at ₹4,324 and shareholder funds at ₹2,267, with a leverage ratio of 0.01.

Item 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017

Assets

Total Assets 4,324 4,108 3,557 3,327 4,633 3,115 3,136 3,911 3,948 3,004
Current Assets 0 0 0 0 0 0 0 0 0 0
Fixed Assets 281 284 321 330 331 387 758 432 325 258

Liabilities

Total Liabilities 0 0 0 0 0 0 0 0 0 0
Current Liabilities 277 252 254 259 272 282 291 317 290 277
Non-Current Liabilities 0 0 0 0 0 0 0 0 0 0

Shareholders' Equity

Total Equity 2,267 1,951 1,778 1,741 2,663 1,478 1,821 2,140 2,057 2,007
Share Capital 169 169 169 169 169 169 169 169 85 85
Reserves & Surplus 2,098 1,782 1,608 1,572 2,494 1,309 1,651 1,970 1,973 1,922

GlaxoSmithKline Pharmaceuticals Income Statement Screener - Profit & Revenue Analysis

Screen GlaxoSmithKline Pharmaceuticals income statement and profit fundamentals. Analyze GLAXO quarterly results. GlaxoSmithKline Pharmaceuticals reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.

For 2026-Sept, revenue was ₹1,256 and net profit was ₹336, equal to earnings per unit of ₹19.83, at an operating margin of 34%.

In that period expenses were ₹782, interest cost ₹1 and tax ₹124. The next period listed, 2026-Jun, shows revenue of ₹982 and net profit of ₹237.

Item 2026-Sept 2026-Jun 2026-Mar 2025-Dec 2025-Sept 2025-Jun 2025-Mar 2024-Dec 2024-Sept 2024-Jun 2024-Mar 2023-Dec 2023-Sept 2023-Jun 2023-Mar

Revenue and Expenses

Revenue 1,256 982 1,031 1,091 1,016 849 1,015 985 1,050 850 962 833 985 815 826
Expenses 782 643 644 670 644 554 641 658 689 584 673 751 668 618 618

Operating Costs and Margins

EBITDA 475 339 387 421 372 295 374 327 361 266 290 83 318 198 208
Operating Profit % 34.00% 31.00% 35.00% 36.00% 34.00% 31.00% 34.00% 31.00% 32.00% 28.00% 28.00% 7.00% 30.00% 19.00% 22.00%
Depreciation 15 16 13 20 17 16 15 19 17 16 18 17 18 16 17
Interest 1 1 1 1 1 0 1 0 0 0 1 0 0 0 1

Profit and Earnings

Profit Before Tax 459 323 373 400 354 279 359 308 344 249 271 65 299 181 190
Tax 124 85 95 104 97 74 96 78 91 67 76 20 82 49 57
Net Profit 336 237 278 296 258 205 263 230 253 182 195 46 218 132 133
EPS 19.83 14.00 16.40 16.54 15.07 12.10 15.52 13.57 14.67 10.76 11.37 9.89 12.84 7.04 7.41

GlaxoSmithKline Pharmaceuticals Cash Flow Screener - Liquidity Fundamentals

Screen GLAXO cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.

In 2026-March, operating activities generated ₹903, and net cash flow was an inflow of ₹563.

Over the same period, investing activities provided ₹397 and financing activities used ₹737.

Item 2026-March 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March 2018-March 2017-March

Cash from Operations and Investing

Operating Activities 903 1,290 582 484 811 578 491 410 473 234
Investing Activities 397 -46 9 808 -406 418 -57 -153 -104 301

Financing and Net Cash

Financing Activities -737 -769 -562 -1,543 -524 -696 -428 -358 -307 -511
Net Cash Flow 563 475 29 -251 -119 300 6 -102 62 24

GlaxoSmithKline Pharmaceuticals Shareholding Pattern Screener

See GlaxoSmithKline Pharmaceuticals shareholding pattern with promoter, FII, and DII holdings. Check GlaxoSmithKline Pharmaceuticals promoter holding and ownership changes for GLAXO on TickJournal, and see how institutional stock price moves affect the market.

In 2026-Mar, promoters held 75.00%, foreign institutions 4.62%, domestic institutions 7.68% and the public 10.35%, spread across 121,763 shareholders.

The shareholder count was 121,763 in 2026-Mar, compared with 126,087 in 2026-Jun.

Item 2026-Mar 2026-Jun 2026-Sept 2025-Mar 2025-Jun 2025-Sept 2025-Dec 2024-Mar

Promoter Holding

Promoter Holding 75.00% 75.00% 75.00% 75.00% 75.00% 75.00% 75.00% 75.00%

Institutional Investors

FII Holding 4.62% 4.79% 4.75% 4.52% 4.89% 4.80% 4.64% 3.48%
DII Holding 7.68% 7.80% 8.48% 7.79% 7.70% 7.75% 7.70% 7.90%

Government, Public and Others

Govt Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Public Holding 10.35% 10.21% 9.65% 10.60% 10.32% 10.34% 10.36% 11.27%
Other Holding 2.35% 2.20% 2.12% 2.09% 2.09% 2.11% 2.30% 2.35%
Shareholder Count 121,763 126,087 119,337 121,885 123,629 122,904 122,460 118,994

Dividend Yield Screener - Share Price & Share Analysis

Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by GlaxoSmithKline Pharmaceuticals. GlaxoSmithKline Pharmaceuticals dividend yield can be compared with peers and other stocks in the market.

The latest dividend recorded was ₹57.00 per unit for 2026-March, a yield of 2.13%, compared with ₹54.00 for 2025-March.

Dividends are listed for 10 periods, with the three most recent payouts at ₹57.00, ₹54.00 and ₹32.00 per unit.

Period Dividend Per Share Dividend Yield
2026-March ₹57.00 2.13%
2025-March ₹54.00 2.37%
2024-March ₹32.00 1.11%
2023-March ₹32.00 1.64%
2022-March ₹90.00 7.05%
2021-March ₹30.00 1.80%
2020-March ₹40.00 2.78%
2019-March ₹20.00 1.59%
2018-March ₹35.00 2.70%
2017-March ₹30.00 2.87%

GlaxoSmithKline Pharmaceuticals Stock Index Membership - Nifty & Sensex

See which indices include GlaxoSmithKline Pharmaceuticals stock. Check GLAXO index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.

The company is listed in 20 indices, including BSE 1000.

Among the benchmarks tracked are BSE 1000, BSE 200 EQUAL WEIGHT, BSE INDEX BSE HC, BSE INDEX BSE200.

Complete Index List

BSE 1000
BSE 200 EQUAL WEIGHT
BSE INDEX BSE HC
BSE INDEX BSE200
BSE INDEX BSE500
BSE INDEX BSEQUI
BSE INDEX LMI250
BSE INDEX MID150
BSE INDEX MIDCAP
BSE INDEX MSL400
NIFTY 500
NIFTY LARGEMID250
NIFTY M150 QLTY50
NIFTY MIDCAP 150
NIFTY MIDSML 400
NIFTY MIDSML HLTH
NIFTY TOTAL MKT
NIFTY500 EQUAL WEIGHT
NIFTY500 LARGEMIDSMALL EQUAL CAP WEIGHTED
NIFTY500 MULTICAP

GlaxoSmithKline Pharmaceuticals Market Events Screener - Corporate Actions

Get GlaxoSmithKline Pharmaceuticals corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check GlaxoSmithKline Pharmaceuticals stock events that may affect GLAXO share price, along with derivatives, futures and options activity and sector gainers.

15 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated November 3, 2026, with a record date of November 3, 2026.

It is followed by Quarterly Result Announcement dated August 3, 2026 and Annual General Meeting dated June 30, 2026.

Announcement Date Record Date Event Type Information Price Impact
2026-11-03 2026-11-03 Quarterly Result Announcement NA 0.00%
2026-08-03 2026-08-03 Quarterly Result Announcement NA 6.86%
2026-06-30 2026-06-30 Annual General Meeting NA -3.82%
2026-05-29 2026-05-29 Dividend ₹ 57.00 /share -6.20%
2026-05-13 2026-05-13 Quarterly Result Announcement NA 0.87%
2026-02-09 2026-02-09 Quarterly Result Announcement NA 1.10%
2025-11-06 2025-11-06 Quarterly Result Announcement NA -3.50%
2025-08-01 2025-08-01 Quarterly Result Announcement NA -3.21%
2025-06-27 2025-06-27 Annual General Meeting NA 21.34%
2025-05-30 2025-05-30 Dividend ₹ 42.00 /share 19.92%
2025-05-13 2025-05-13 Quarterly Result Announcement NA -7.08%
2025-02-14 2025-02-14 Quarterly Result Announcement NA -3.77%
2024-11-07 2024-11-07 Dividend ₹ 12.00 /share -0.47%
2024-10-29 2024-10-29 Quarterly Result Announcement NA 0.52%
2024-06-28 2024-06-28 Annual General Meeting NA 32.30%

GlaxoSmithKline Pharmaceuticals Competitors Screener - Peer Stocks Comparison

Screen GLAXO competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.

The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.

Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Sun Pharmaceutical 451,075 41.20 61,674 12.69% 11,565 63.60
Divis Laboratories 303,749 90.40 11,067 13.95% 2,568 78.53
Torrent Pharmaceuticals 177,632 85.50 13,886 20.34% 2,138 47.27
Laurus Labs 130,972 97.10 6,868 22.01% 890 69.60
Zydus Life Science 118,693 28.00 27,658 17.64% 5,026 52.34
Dr Reddys Laboratories 115,186 42.00 35,059 3.90% 4,158 70.24
Cipla 112,438 39.90 29,045 2.24% 3,870 54.92
Mankind Pharma 109,044 48.10 14,636 14.85% 1,938 65.43
Aurobindo Pharma 104,903 26.00 34,145 5.56% 3,503 66.06
Lupin 90,557 17.60 29,039 26.75% 5,356 44.92

GlaxoSmithKline Pharmaceuticals Company Announcements - News & Reports Screener

Screen GLAXO latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.

20 recent announcements are listed, the latest dated November 13, 2026.

The next most recent announcements are dated November 10, 2026 and November 10, 2026.

Date Update Actions
2026-11-13 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome -
2026-11-10 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome -
2026-11-10 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-11-09 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome -
2026-11-09 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -
2026-11-03 Announcement under Regulation 30 (LODR)-Press Release / Media Release -
2026-11-03 Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s -
2026-11-03 Announcement under Regulation 30 (LODR)-Change in Management -
2026-11-03 Standalone And Consolidated Financial Results For The Second Quarter & Half Year Ended 30Th September 2026 -
2026-11-03 Board Meeting Outcome for Outcome Of Meeting -
2026-10-28 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -
2026-10-13 Board Meeting Intimation for To Consider Approve And Take On Record The Un-Audited Financial Results For The Second Quarter & Half Year Ended 30Th September 2026. -
2026-10-12 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 -
2026-09-25 Closure of Trading Window -
2026-09-15 Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot -
2026-09-15 Shareholder Meeting / Postal Ballot-Scrutinizer"s Report -
2026-09-02 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-09-01 Corrigendum To The Notice Of Postal Ballot Dated August 3 2026 -
2026-08-26 Volume Movement Letter -
2026-08-26 Clarification sought from GlaxoSmithKline Pharmaceuticals Ltd -

Frequently Asked Questions

How is the company valued right now?

The current quote is ₹2,638.20, within a 52-week range of ₹2,103.20 to ₹3,106.40. The P/E ratio is 39.20 and the P/B ratio is 23.91, with earnings per unit of ₹61.15. Market capitalisation stands at ₹45,275.46 Cr and the dividend yield is 2.15%. The company operates in the Healthcare sector, in the Pharmaceuticals & Biotechnology industry, so compare these ratios with its sector peers in the table above.

About This Data

Quotes are sourced from the NSE and the BSE. Key statistics were last updated on November 19, 2026. This page covers 10 balance sheet periods, 15 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.